TRDA

Healthcare Biotechnology

Entrada Therapeutics, Inc.

$5.38

-0.41 -7.08% today

Price History

Not enough data

Key Stats

Market Cap

209.48M

Avg Volume

360,543

EPS

-$3.96

52W High

$16.45

52W Low

$5.17

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.79

P/B Ratio

0.83

P/S Ratio

44.70

EV/EBITDA

-0.11

EV/Revenue

4.17

Margins

Gross Margin 0.0%

Operating Margin (5007.0%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(53.9%)

Return on Equity

(54.1%)

Return on Assets

(29.2%)

Liquidity & Leverage

Current Ratio

10.89

Quick Ratio

10.52

Debt / Equity

0.21

Total Cash

223.00M

Total Debt

48.54M

About

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.